Valganciclovir for Suppression of Human Herpesvirus–8 Replication: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Trial
- 1 July 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 198 (1), 23-30
- https://doi.org/10.1086/588820
Abstract
Background. Human herpesvirus–8 (HHV-8) replication is critical in the induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and some cases of Castleman disease. In vitro and observational studies suggest that ganciclovir inhibits HHV-8 replication, but no randomized clinical trials have been conducted. Methods. A total of 26 men infected with HHV-8 were randomized to receive 8 weeks of valganciclovir administered orally (900 mg once per day) or 8 weeks of placebo administered orally. After a 2-week washout period, participants in each group received the study drug they had not yet taken (either valganciclovir or placebo), for 8 additional weeks. Oral swab samples were collected daily during the study, and HHV-8 and CMV DNA were quantified by real-time PCR. Results. A total of 16 human immunodeficiency virus (HIV)–positive men and 10 HIV-negative men enrolled in and completed the study. Of the 3439 swab samples that participants had been expected to provide, 3029 (88%) were available for analysis. HHV-8 was detected on 44% of swabs collected from participants who were receiving placebo, compared with 23% of swabs collected from participants who were receiving valganciclovir (relative risk [RR], 0.54 [95% confidence interval {CI}, 0.33–0.90]; P = .02). Valganciclovir reduced oropharyngeal shedding of cytomegalovirus by 80% (RR, 0.20 [95% CI, 0.08–0.48]; P < .001). Shedding of HHV-8 and shedding of cytomegalovirus were independent. Hematologic, renal, or hepatic toxicities were no more common among participants who received the active drug, compared with those who received placebo, though participants who received valganciclovir reported more days of diarrhea. Conclusions. Valganciclovir administered orally once per day is well tolerated and significantly reduces the frequency and quantity of HHV-8 replication.Keywords
This publication has 44 references indexed in Scilit:
- Frequent and Asymptomatic Oropharyngeal Shedding of Human Herpesvirus 8 among Immunocompetent MenThe Journal of Infectious Diseases, 2007
- Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapyAIDS, 2006
- Prevalence of Human Herpesvirus-8 Salivary Shedding in HIV Increases with CD4 CountJournal of Dental Research, 2004
- Reduced Levels of Neutralizing Antibodies to Kaposi Sarcoma–Associated Herpesvirus in Persons with a History of Kaposi SarcomaThe Journal of Infectious Diseases, 2004
- Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatmentBlood, 2004
- Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma: Implications for the Design of Therapeutic Trials in Patients With Advanced, Symptomatic Kaposi's SarcomaJournal of Clinical Oncology, 2004
- A Pilot Study of Cidofovir in Patients with Kaposi SarcomaThe Journal of Infectious Diseases, 2003
- Detection of DNA of Lymphotropic Herpesviruses in Plasma of Human Immunodeficiency Virus-Infected Patients: Frequency and Clinical SignificanceClinical and Vaccine Immunology, 2002
- Analysis of Longitudinal DataTechnometrics, 1995
- Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDSThe Lancet, 1992